Dicobalt octacarbonyl

CAS：10210-68-1

Molecular Formula：Co2(CO)₈

Vitamin D2

CAS：50-14-6

Molecular Formula：C₂₈H₄₄O

Hydrocortisone acetate

CAS：50-03-3

Molecular Formula：C₂₃H₃₂O₆

Cortisone acetate

CAS：50-04-4

Molecular Formula：C₂₃H₃₀O₆

Phenobarbital

CAS：50-06-6

Molecular Formula：C₁₂H₁₂N₂O₃

Mitomycin C

CAS：50-07-7

Molecular Formula：C₁₅H₁₈N₄O₅

Oxyphenonium bromide

CAS：50-10-2

Molecular Formula：C₂₁H₃₄BrNO₃

(±)-Mephenytoin

CAS：50-12-4

Molecular Formula：C₁₂H₁₄N₂O₂

N-Acetyl-D-alanine

CAS：19436-52-3

Molecular Formula：C₅H₉NO₃

5-bromo-3,3-dimethyl-2,3-dihydro-1H-isoindol-1-one

CAS：959756-18-4

Molecular Formula：C10H10BrNO

2,2-Dimethylpropylamine hydrochloride

CAS：15925-18-5

Molecular Formula：C₅H₁₃N.HCl

(1R,3S,5R)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid

CAS：1306734-44-0

Molecular Formula：C12H19NO4

4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid

CAS：641569-94-0

Molecular Formula：C₁₇H₁₄N₄O₂

(3,3-Difluoro-1-Methyl-cyclobutyl)Methanol

CAS：1408076-35-6

Molecular Formula：C6H10F2O

2-hydroxy-4-tetradecyl-1,3,2-dioxaborolane

CAS：84819-41-0

Molecular Formula：C16H33BO3

3-(Trifluoromethyl)benzaldehyde

CAS：454-89-7

Molecular Formula：C₈H₅F₃O

11-26

Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease

Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel oxidative stress stabilizers for the treatment of ocular diseases, today announced that all primary and secondary endpoints of an ex-U.S. vehicle-cont

11-15

Janssen Licenses "Flexible Antibody" Technology from F-star in New Collab

Clinical-stage biopharma company F-star Therapeutics announced a new partnership with Janssen Biotech on Wednesday, only one month after presenting an optimistic trial-in-progress update to the public on its tetravalent dual T-cell agonist FS120 at the Eu

11-09

Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced it will present new preclinical data on the company’s lead immuno-oncology program, E

原料药进口

IMPORT OF APIS

中间体研发及生产

参比制剂进口

IMPORT OF REFERENCEPREPARATIONSINTERMEDI

兽药原料

VETERINARY DRUG RAW MATERIALS